WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to ...
WILMINGTON, Del. -- (BUSINESS WIRE)-- Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback